Business UpdateAug 4, 2026, 09:19 AM
Immix Biopharma to Attend Morgan Stanley Global Healthcare Conference
AI Summary
Immix Biopharma, Inc. announced its participation in the Morgan Stanley 24th Annual Global Healthcare Conference from September 14-16, 2026, in New York, NY. The company will host one-on-one meetings with institutional investors during the event. Immix Biopharma is a global leader in AL Amyloidosis, with its lead candidate NXC-201 having received Breakthrough Therapy Designation, Regenerative Medicine Advanced Therapy, and Orphan Drug Designation from the US FDA and EMA.
Key Highlights
- Immix Biopharma to participate in Morgan Stanley 24th Annual Global Healthcare Conference.
- Conference scheduled for September 14-16, 2026, in New York, NY.
- Company will host one-on-one meetings with institutional investors.
- Immix Biopharma is a global leader in relapsed/refractory AL Amyloidosis.
- Lead candidate NXC-201 has US FDA Breakthrough Therapy Designation (BTD) and RMAT.
- NXC-201 also has Orphan Drug Designation (ODD) from FDA and EMA.
Price Impact
More from IMMX